Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Grazoprevir/ruzasvir/uprifosbuvir - Merck & Co

Next Previous
Drug Profile

Grazoprevir/ruzasvir/uprifosbuvir - Merck & Co

Alternative Names: Grazoprevir/MK-3682/MK-8408; Grazoprevir/MK-3682/ruzasvir; Grazoprevir/ruzasvir/MK-3682; Grazoprevir/uprifosbuvir/ruzasvir; MK-3682/grazoprevir/ruzasvir; MK-3682/ruzasvir/grazoprevir; MK-3682B; MK-5172/MK-3682/MK-8408; MK3; Ruzasvir/grazoprevir/MK-3682; Ruzasvir/grazoprevir/uprifosbuvir; Ruzasvir/MK-3682/grazoprevir; Ruzasvir/uprifosbuvir/grazoprevir; Uprifosbuvir/grazoprevir/ruzasvir; Uprifosbuvir/ruzasvir/grazoprevir

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Class Antivirals; Benzoxazines; Cyclopropanes; Imidazoles; Indoles; Macrocyclic compounds; Pyrimidines; Pyrrolidines; Quinoxalines; Small molecules; Thiazoles; Uracil nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 07 Dec 2017 Chemical structure information added
  • 29 Sep 2017 Discontinued - Phase-III for Hepatitis C in Denmark, Lithuania (PO)
  • 29 Sep 2017 Merck terminates a phase II trial in Hepatitis C based on a review of phase II efficacy data in Belgium (PO) (EudraCT2016-000620-26)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top